Compare Gilead Sciences, Inc. (GILD) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Vanguard Short Term Corporate Bond ETF trades at $77.34 (market cap $51.90B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× Vanguard Short Term Corporate Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| GILD | VCSH | |
|---|---|---|
Market Cap | $182.40B | $51.90B |
Volume | 4,469,821 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $80.20 |
52-Week Low | $116.74 | $77.03 |
Typical Hold Time | 111 Days | 52 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.27 with a slight 0.08% daily gain. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF offers a competitive yield and low expense ratio, but faces headwinds from tight credit spreads and a cautious market outlook. Recent news highlights its role as a stable income alternative to CDs or stable value funds, with institutional activity showing mixed positioning.
The outlook for VCSH is neutral with limited upside due to unattractive entry points and constrained credit spreads. Its short duration minimizes interest rate risk, but yield advantages over peers may narrow. Key risks include corporate credit deterioration and Fed policy shifts. Investors seeking short-term, high-quality bond exposure may find value, but current levels offer modest total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
